CAR-dependent anti-metastatic activity of modified NK cell line YT
- Authors: Koval O.A1,2, Subrakova V.G2,3, Nushtaeva A.A1, Belovezhets T.N3, Troitskaya O.A1, Ermakov M.S1,2, Varlamov M.E1,2, Chikaev A.N3, Kuligina E.V1, Kulemzin S.V3, Gorchakov A.A2,3, Taranin A.V2,3, Richter V.A1
-
Affiliations:
- Institute of Chemical Biology and Fundamental Medicine SB RAS
- Novosibirsk State University
- Institute of Molecular and Cellular Biology SB RAS
- Issue: Vol 14, No 4 (2019)
- Pages: 66-71
- Section: Articles
- URL: https://genescells.ru/2313-1829/article/view/122213
- DOI: https://doi.org/10.23868/201912034
- ID: 122213
Cite item
Abstract
Keywords
Full Text
About the authors
O. A Koval
Institute of Chemical Biology and Fundamental Medicine SB RAS; Novosibirsk State University
Email: o_koval@ngs.ru
Novosibirsk, Russia
V. G Subrakova
Novosibirsk State University; Institute of Molecular and Cellular Biology SB RAS
Email: o_koval@ngs.ru
Novosibirsk, Russia
A. A Nushtaeva
Institute of Chemical Biology and Fundamental Medicine SB RAS
Email: o_koval@ngs.ru
Novosibirsk, Russia
T. N Belovezhets
Institute of Molecular and Cellular Biology SB RAS
Email: o_koval@ngs.ru
Novosibirsk, Russia
O. A Troitskaya
Institute of Chemical Biology and Fundamental Medicine SB RAS
Email: o_koval@ngs.ru
Novosibirsk, Russia
M. S Ermakov
Institute of Chemical Biology and Fundamental Medicine SB RAS; Novosibirsk State University
Email: o_koval@ngs.ru
Novosibirsk, Russia
M. E Varlamov
Institute of Chemical Biology and Fundamental Medicine SB RAS; Novosibirsk State University
Email: o_koval@ngs.ru
Novosibirsk, Russia
A. N Chikaev
Institute of Molecular and Cellular Biology SB RAS
Email: o_koval@ngs.ru
Novosibirsk, Russia
E. V Kuligina
Institute of Chemical Biology and Fundamental Medicine SB RAS
Email: o_koval@ngs.ru
Novosibirsk, Russia
S. V Kulemzin
Institute of Molecular and Cellular Biology SB RAS
Email: o_koval@ngs.ru
Novosibirsk, Russia
AA. A Gorchakov
Novosibirsk State University; Institute of Molecular and Cellular Biology SB RAS
Email: o_koval@ngs.ru
Novosibirsk, Russia
A. V Taranin
Novosibirsk State University; Institute of Molecular and Cellular Biology SB RAS
Email: o_koval@ngs.ru
Novosibirsk, Russia
V. A Richter
Institute of Chemical Biology and Fundamental Medicine SB RAS
Email: o_koval@ngs.ru
Novosibirsk, Russia
References
- Кулемзин С.В., Кузнецова В.В., Мамонкин М. и др. Основы дизайна химерных антигенных рецепторов. Acta Naturae 2017; 9: 6-15.
- Chiossone L., Dumas P.Y., Vienne M. et al. Natural killer cells and other innate lymphoid cells in cancer. Nat. Rev. Immunol. 2018; 18: 671-88.
- Lorenzo-Herrero S., Lôpez-Soto A., Sordo-Bahamonde C. et al. NK cell-based immunotherapy in cancer metastasis. Cancers 2018; 11: 29.
- Arabi F., Torabi-Rahvar M., Shariati A. et al. Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials. Experimental Cell Research 2018; 369: 1-10.
- Mannweiler S., Amersdorfer P., Trajanoski S. et al. Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis. Pathol. Oncol. Res. 2009; 15: 167-72.
- Hillerdal V., Essand M. Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer. BioDrugs 2015; 29: 75-89.
- Rehman A.U., Rahman M.U., Khan M.T. et al. The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer. CPD 2019; 24: 3767-77.
- Коваль О.А., Волкова О.Ю., Горчаков А.А. и др. Сравнительный анализ активности лактаптина, полученного в про- и эукариотических системах экспрессии. Вавиловский журнал генетики и селекции 2017; 21: 764-9.
- Субракова В.Г., Кулемзин С.В., Беловежец Т.Н. и др. Нокаут гена Shp-2 приводит к повышению CAR-опосредованной цитотоксичности NK-клеток линии YT. Вавиловский журнал генетики и селекции. В печати 2019. (Subrakova V.G., Kulemzin S.V., Belovezhets T.N. et al. Shp-2 gene knockout upregulates CAR-driven cytotoxicity of YT
- Kingston R.E., Chen C.A., Rose J.K. Calcium Phosphate Transfection. Current Protocols in Molecular Biology 2003; 63: 9.1.1-11.
- O’Doherty U., Swiggard W.J., Malim M.H. Human Immunodeficiency Virus Type 1 Spinoculation Enhances Infection through Virus Binding. Journal of Virology 2000; 74: 10074-80.
- Nushtaeva A.A., Karpushina A.A., Ermakov M.S. et al. Establishment of primary human breast cancer cell lines using “pulsed hypoxia” method and development of metastatic tumor model in immunodeficient mice. Cancer Cell Int. 2019; 19: 46.
- Кулемзин С.В., Чикаев Н.А., Волкова О.Ю. и др. Модульная система лентивирусных векторов для работы с химерными антигенными рецепторами. Биоорганическая Химия 2017; 43: 124-32. (Kulemzin S.V., Chikaev N.A., Volkova O.Y. et al. Modular lentiviral vector system for chimeric antigen receptor design optimization. Russian Journal of Bioorganic Chemistry 2017; 43: 124-32).
- Rosenbaum L. Tragedy, Perseverance, and Chance - The Story of CAR-T Therapy. N. Engl. J. Med. 2017; 377: 1313-5.
- Shultz L.D., Lyons B.L., Burzenski L.M. et al. Human Lymphoid and Myeloid Cell Development in NOD/LtSz-scid IL2R y nul Mice Engrafted with Mobilized Human Hemopoietic Stem Cells. J. Immunol. 2005; 174: 6477-89.
- Deng Z., Wu Y., Ma W. et al. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunol. 2015; 16: 1.
- Zhang Q., Zhang H., Ding J. et al. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models. Journal of Immunology Research 2018; 2018: 1-11.
- Bubendorf L., Schopfer A., Wagner U. et al. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Human Pathology 2000; 31: 578-83.
- Ren D., Yang Q., Dai Y. et al. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-kB signaling pathway. Mol. Cancer 2017; 16: 117.
- Chowdhury D., Lieberman J. Death by a Thousand Cuts: Granzyme Pathways of Programmed Cell Death. Annu. Rev. Immunol. 2008; 26: 389-420.
- Shah N.N., Fry T.J. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 2019; 16: 372-85.
- Martinez M., Moon E.K. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front. Immunol. 2019; 10: 128.